gms | German Medical Science

62. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS)

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie

17.09. - 21.09.2017, Oldenburg

5 Clinical Trials

Meeting Abstract (Abstr. 048)

Recent advances in the analysis of adverse events at varying follow-up times in the benefit assessment of therapies: recommendations by the ATF / APF project group

Unkel S, Ose C, Knoerzer D, Skipka G, Langer F, Schmoor C, Proctor T, Beyersmann J, Gillhaus J, Friede T
[Full Text]
Meeting Abstract (Abstr. 052)

Netzwerk Meta-Analyse für zielgerichtete Therapieoptionen

Jensen K, Proctor T, Kieser M
[Full Text]
Meeting Abstract (Abstr. 088)

Durchführen geplanter und ungeplanter Zwischenanalysen in Klinischen Studien

Eveslage M, Ligges S, Ehrhardt S, Müller H, Faldum A
[Full Text]
Meeting Abstract (Abstr. 131)

Fallzahlkorrektur bei Powerverlust durch Imbalancen der Blockrandomisation am Beispiel des t-Tests

Muche R, Rohlmann F, Dreyhaupt J
[Full Text]
Meeting Abstract (Abstr. 133)

Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials with multiple endpoints are performed

Preussler S, Kieser M, Kirchner M
[Full Text]
Meeting Abstract (Abstr. 159)

Inference for diffusion processes with point of equilibrium and application to personalized pediatric oncology

Schmidt R, Faldum A
[Full Text]
Meeting Abstract (Abstr. 161)

Optimized Rules and Performance Criteria for Adaptive Designs with Sample Size Recalculation

Rauch G, Kieser M, Kunzmann K
[Full Text]
Meeting Abstract (Abstr. 165)

A Systematic Comparison of Recurrent Event Models for the Application to Composite Endpoints

Ozga AK, Rauch G, Kieser M
[Full Text]
Meeting Abstract (Abstr. 285)

Wilcoxon-Mann-Whitney test for non-inferiority in the presence of death-censored observations – power considerations

Schmidtmann I, Konstantinides S, Binder H
[Full Text]
Meeting Abstract (Abstr. 155)

Investigation of the added benefit of new markers for the prediction of adverse kidney events in patients after cardiac surgery using different measures in raw and cross-validated versions

Kropf S, Albert C
[Full Text]
Meeting Abstract (Abstr. 237)

An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: Design of a concept evaluation in a double-blind randomised placebo-controlled phase II study

Heßler N, Kasten M, Berg D, Brüggemann N, Gasser T, Krockenberger K, Olbrich D, Prasuhn J, Klein C, Ziegler A
[Full Text]
Meeting Abstract (Abstr. 251)

Einfluss informativer a-priori Verteilungen in linearen gemischten Modellen für die longitudinale Analyse von Daten zur Lebensqualität

Koch R, Schumacher A
[Full Text]
Meeting Abstract (Abstr. 257)

Lessons Learned from a Clinical Investigation: Data Processing Aspects of the DiaFu-Study

Krüger P, Seidel D, Bauer S
[Full Text]
Meeting Abstract (Abstr. 042)

MedDRA Coding tool – Studiendaten effektiv kodieren

Bergmann E, Hahmann M
[Full Text]
Meeting Abstract (Abstr. 091)

Klinische Arzneimittelforschung – Neuerungen und Herausforderungen

Chase D
[Full Text]
Meeting Abstract (Abstr. 218)

Planung und Auswertung von Non-Inferiority-Studien

Hoffmann V, Adolf D, Weiß C
[Full Text]